AMPK:regulating energy balance at the cellular and whole body levels by Hardie, D. Grahame & Ashford, Michael L. J.
                                                              
University of Dundee
AMPK
Hardie, D. Grahame; Ashford, Michael
Published in:
Physiology
DOI:
10.1152/physiol.00050.2013
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Hardie, D. G., & Ashford, M. L. J. (2014). AMPK: regulating energy balance at the cellular and whole body
levels. Physiology, 29(2), 99-107. DOI: 10.1152/physiol.00050.2013
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 14. Dec. 2017
AMPK: Regulating Energy Balance at
the Cellular and Whole Body Levels
AMP-activated protein kinase appears to have evolved in single-celled eu-
karyotes as an adenine nucleotide sensor that maintains energy homeostasis
at the cellular level. However, during evolution of more complex multicellular
organisms, the system has adapted to interact with hormones so that it also
plays a key role in balancing energy intake and expenditure at the whole body
level.
D. Grahame Hardie,
and Michael L. J. Ashford
Division of Cell Signalling & Immunology, College of Life
Sciences, and Division of Cardiovascular and Diabetes Medicine,
College of Medicine, Dentistry & Nursing, University of Dundee,
Dundee, Scotland, United Kingdom
Although discovered via its ability to phosphory-
late and inactivate two enzymes involved in lipid
synthesis, i.e., acetyl-CoA carboxylase and HMG-
CoA reductase (6, 9, 10), the AMP-activated protein
kinase (AMPK) is now recognized to have dozens of
downstream targets (23–25, 53) and may turn out
to have hundreds. Its principal role is as an energy
sensor monitoring the cellular ratios of AMP to ATP
and/or ADP to ATP (20). Once switched on by
stresses that increase these ratios, it activates cat-
abolic pathways that generate ATP while switching
off nonessential ATP-requiring processes, thus act-
ing to restore energy homeostasis. Although it ap-
pears to have evolved in single-celled eukaryotes as
a cell-autonomous energy sensor, in multicellular
organisms, its role has adapted so that it also re-
sponds to hormones regulating whole-body energy
balance. The aim of this review is to discuss these
two distinct levels at which the AMPK system op-
erates. Given the very large number of papers now
published on AMPK, it is unfortunately not possi-
ble to provide comprehensive coverage.
AMPK- and SNF1-Related Kinases:
Roles in Lower Eukaryotes
AMPK appears to exist universally as heterotri-
meric complexes comprised of catalytic -subunits
and regulatory - and -subunits (FIGURE 1), and
well conserved genes encoding these can be found
in the genomes of essentially all eukaryotes, in-
cluding protists, fungi, plants, and animals (26). It
is therefore likely that AMPK arose at a very early
stage during eukaryotic evolution. A critical event
in the genesis of eukaryotes is thought to have
been the engulfment by archaeal cells of oxidative
bacteria that became the mitochondria that al-
lowed eukaryotes to generate ATP by oxidative me-
tabolism utilizing molecular oxygen. What would
have been needed at that time would have been a
system to monitor the output of the primitive mi-
tochondria and modulate their cellular content
and function according to the energy demands of
the host cell; this remains one of the key functions
of AMPK today.
Genes encoding the - and -subunits of the
AMPK ortholog in the yeast Saccharomyces cerevi-
siae (SNF1 and SNF4) were cloned in the 1980s (11,
12), although their relationship with AMPK was not
recognized until 1994 (51, 76). If yeast are grown
in batch culture in high glucose, they initially grow
rapidly using only fermentation (glycolytic metab-
olism of glucose to ethanol) to generate ATP. How-
ever, when glucose runs low, growth pauses as
genes required for mitochondrial oxidative metab-
olism (previously repressed by glucose) are
switched on. Growth then resumes at a lower rate,
a phenomenon termed the diauxic shift. The
switch to oxidative metabolism allows more effi-
cient ATP generation from the remaining glucose
as well as from ethanol generated during the fer-
mentation phase, but yeast with snf1 or snf4 mu-
tations are unable to perform this switch and do
not display the diauxic shift (27). They are also
unable to switch on genes required for growth on
other fermentable carbon sources, such as sucrose
or raffinose (11, 12).
AMPK orthologs are also found in plants, where
they are termed SNF1-related kinases (SnRK1 sub-
family) (58). In the moss Physcomitrella patens,
plants are viable if both SnRK1 catalytic subunits
are deleted, but only if continuously illuminated;
they fail to grow on a normal daily light/dark cycle
(68). In the higher plant Arabidopsis thaliana, si-
lencing of both SnRK1 catalytic subunits leads to a
severe growth defect and failure to upregulate ex-
pression of genes required during darkness (5).
Thus SnRK1 kinases are required for the response
to darkness, the equivalent of starvation in plants.
In the nematode worm Caenorhabditis elegans, the
AMPK ortholog is required for the lifespan exten-
sion that occurs in response to dietary restriction
and other stresses (4, 21). Taken together, these
findings suggest that the ancestral role of AMPK
was in the response to starvation for a carbon
source.
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AMPK and SNF1 Complexes:
Regulation by Adenine Nucleotides
As with many other protein kinases, AMPK and its
orthologs are only significantly active when phos-
phorylated at a conserved threonine within the
kinase domain by upstream kinases (FIGURE 1);
this threonine is usually referred to as Thr172 due
to its position in the rat 2-subunit sequence (29).
In mammals, the principal upstream kinase phos-
phorylating Thr172 is a heterotrimeric complex
containing the tumor suppressor kinase LKB1 (28,
64, 75, 82). This complex has a high basal activity
and appears to be constitutively active (61), but its
ability to phosphorylate Thr172 is enhanced by
conformational changes in its substrate, AMPK,
caused by binding of AMP to the -subunit
(FIGURE 1). AMP binding also inhibits Thr172 de-
phosphorylation (20), and it was recently reported
that this effect of AMP was mimicked by binding of
ADP (78). Although this has been confirmed, the
effects of ADP are 10-fold less potent than those of
AMP, and the much larger increases in AMP that
occur in cells treated with mitochondrial inhibitors
suggest that AMP might remain the more physio-
logically relevant signal (20). Recent reports that
ADP binding also promoted Thr172 phosphoryla-
tion (55) could not be confirmed (20).
Via these two effects, AMP binding causes a sen-
sitive switch to the active, phosphorylated form of
AMPK. This activation is further amplified by allo-
steric activation, which is triggered only by AMP
(FIGURE 2). The physiological significance of allo-
steric activation has been questioned (8, 54) on the
grounds that AMP might have difficulty competing
with the much higher cellular concentrations of
ATP and ADP. However, recent studies show that
AMP concentrations from 50 to 500 M cause a
large allosteric activation (10-fold) in cell-free as-
says, even in the presence of much higher ATP
concentrations (5 mM) that are within the physio-
logical range. Cellular AMP concentrations also in-
creased over a similar range (40 –270 M) when
cultured human cells were treated with the mito-
chondrial inhibitor berberine (20). Furthermore,
when AMPK carrying a phosphomimetic T172D
mutation, which retains allosteric activation by
AMP (65), was expressed in AMPK-null mouse em-
bryo fibroblasts, the phosphorylation of the down-
stream target ACC (which was absent in the
untransfected cells) was markedly stimulated by
berberine (20). Since the T172D mutant cannot be
phosphorylated at Thr172, this effect can only have
been due to allosteric activation.
Thus mammalian AMPK is activated by AMP by
a tripartite mechanism: 1) promotion of Thr172
phosphorylation; 2) inhibition of Thr172 dephos-
phorylation; 3) allosteric activation. Only the sec-
ond effect is mimicked by ADP, although all three
are antagonized by ATP (FIGURE 2). When cells
were treated with berberine, the decreases in ATP
(20%) and increases in ADP (approximately two-
fold) were much smaller than the increases in AMP
(six- to sevenfold) (20). Thus mammalian AMPK
may have evolved to respond primarily to AMP
because it is the most sensitive indicator of energy
stress, despite its low cellular concentration.
Surprisingly, allosteric activation by AMP is only
observed in AMPK orthologs from animal species,
including insects (56) and nematodes (4), and not
in those from fungi (73, 76) or plants (45). The
fungal and plant orthologs are still modulated by
reversible phosphorylation of the residue equiva-
lent to Thr172; in S. cerevisiae, phosphorylation of
this residue (Thr210) increases in response to glu-
cose starvation and correlates with large increases
in cellular ADP-to-ATP and AMP-to-ATP ratios
(73). Recently, it has been reported that binding of
ADP, but not AMP, to the yeast SNF1 complex
protects against dephosphorylation of Thr210 (48),
FIGURE 1. Domain structure of eukaryotic AMPK
orthologs
The catalytic -subunits contain conventional serine/thre-
onine kinase domains containing the threonine residue
(Thr172 in rat 2) phosphorylated by upstream kinases.
The kinase domains are followed (at least in vertebrates)
by small domains with a negative effect on kinase activ-
ity (auto-inhibitory domains), which are joined to the
COOH-terminal domains (-CTD) by a less well con-
served linker. In vertebrates, there is also a flexible ser-
ine-/threonine-rich loop (ST loop) within the -CTD that
is phosphorylated by Akt. The -subunits contain two
conserved regions, a carbohydrate-binding module
(CBM) that causes the mammalian complex to bind to
glycogen particles, and a COOH-terminal domain (-
CTD) that provides the bridge between the - and
-subunits. The -subunits contain variable NH2-terminal
regions followed by a short sequence involved in bind-
ing to the -subunit, then four tandem repeats of a cys-
tathionine--synthase (CBS) motif. These act in pairs to
form the binding sites for adenine nucleotides; in mam-
malian AMPK, there is one site between CBS1 and CBS2
and two between CBS3 and CBS4.
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suggesting that ADP, rather than AMP, may be the
critical activating signal in fungi.
AMPK: Regulation by Ca2- and
Calmodulin-Dependent
Protein Kinases
Treatment of cells with agents that increase intracel-
lular Ca2 cause increased Thr172 phosphorylation,
even in tumor cells lacking LKB1. This led to the
realization that AMPK activation by the calmodulin-
dependent protein kinase kinases (CaMKKs), first
demonstrated 10 years earlier (31), was physio-
logically relevant, particularly with the CaMKK
(CaMKK2) isoform (30, 34, 74) (FIGURE 2). In-
creases in cytosolic Ca2 often trigger energy-re-
quiring processes such as contraction or secretion
and also require ATP expenditure to pump Ca2
back out of the cytosol. AMPK activation by the
Ca2-CaMKK pathway may in part be a mecha-
nism to anticipate this demand for ATP before it
has occurred. This pathway also provides a mech-
anism for hormones that increase cytosolic Ca2 to
activate AMPK. Physiological situations where this
pathway operates include depolarization of neu-
rons (30), activation of T cells via their antigen
receptor (67), and treatment of cells with agents
that activate G-protein-coupled receptors (GPCRs)
coupled to release of cytosolic Ca2 (including
ghrelin; see below).
AMPK: Regulation by
TGF--Activated Kinase-1
In 2006, Carlson and coworkers reported results of
screening a mouse embryo library for DNAs that
would restore growth on raffinose to an S. cerevi-
siae strain that lacked all three kinases upstream of
the yeast AMPK ortholog (52). As well as LKB1 and
CaMKK, this screen identified TGF--activated
kinase-1 (TAK1) as a potential upstream kinase for
AMPK. This was a surprise, because TAK1 is best
known for its involvement in signaling from recep-
tors for pro-inflammatory cytokines and from toll-
like receptors involved in innate immunity (16). In
the same year, Schneider’s group reported that
knocking out TAK1 in mouse embryo fibroblasts
reduced phosphorylation of Thr172 on AMPK in
response to several AMPK activators such as oligo-
mycin or metformin (79). However, in contrast to
Carlson’s group, who showed that TAK1 directly
phosphorylated Thr172 in cell-free assays (52),
they proposed a pathway in which oligomycin or
metformin activated TAK1, which in turn activated
LKB1 by some unspecified mechanism, leading to
Thr172 phosphorylation by LKB1. This is difficult
to reconcile with the well established mechanisms
described in an earlier section, where these same
agents increase AMP that binds to the AMPK-
subunit, promoting net phosphorylation by LKB1.
Since 2006, there have been few further reports
that help to clarify the potential link between TAK1
and AMPK, although it was reported that tumor
necrosis factor-related apoptosis-inducing ligand
(TRAIL) activated AMPK in cultured breast cancer
cells via a mechanism that was LKB1 and CaMKK
independent but TAK1 dependent (32).
Regulation of AMPK by the
Insulin-Activated Kinase Akt
AMPK is activated during times of energy stress,
when it inhibits growth and promotes catabolism
and breakdown of energy stores. By contrast, insu-
lin is an anabolic hormone released during times of
nutrient excess, which promotes growth and en-
ergy storage. It is therefore not surprising that
there should be antagonism between these two
pathways. The insulin-activated kinase Akt has
been shown to phosphorylate the 1 catalytic sub-
unit of AMPK at Ser485 (rat numbering). This ap-
peared to reduce the rate of subsequent Thr172
phosphorylation and activation by LKB1 in a cell-free
assay, whereas prior insulin treatment also reduced
Thr172 phosphorylation during ischemia in perfused
rat hearts (33). This mechanism also occurs in hu-
man hepatocytes infected with hepatitis C virus
FIGURE 2. Regulation of mammalian AMPK by ade-
nine nucleotides and Ca2
Cellular energy stress leads to net conversion of ATP to ADP,
some of which is converted to AMP by the adenylate kinase
reaction (2ADP ↔ ATP  AMP), which maintains AMP at low
levels in unstressed cells. AMP then activates AMPK by three
mechanisms, all of which are due to binding to one or more
sites on the AMPK- subunit: 1) promoting Thr172 phosphory-
lation by LKB1; 2) inhibiting Thr172 dephosphorylation by pro-
tein phosphatases; 3) allosteric activation. Only mechanism 2 is
mimicked by ADP, and then only at higher concentrations than
AMP (20). AMPK can also be activated by increases in cytoso-
lic Ca2, which triggers direct phosphorylation of Thr172 by
CaMKK.
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(when Akt is activated) and appears to be neces-
sary for efficient viral replication (46). Interestingly,
Ser485 lies in a loop of 	55 residues that appears
to be flexible in its unphosphorylated state, being
poorly resolved in a partial crystal structure of
AMPK expressed in bacteria (77). We now term this
the “ST loop” (FIGURE 1) because it is highly ser-
ine/threonine rich; it is absent in orthologs from
invertebrates, fungi, and plants but well conserved
in vertebrates. The ST loop is also phosphorylated
by PKA at Ser485 (35) and by GSK3 at other sites
(66), suggesting that it may have additional regu-
latory functions. The AMPK-2 isoform contains a
residue equivalent to Ser485 (Ser491). Although it
has not yet been definitively shown that phosphor-
ylation of Ser491 has the same inhibitory effect on
LKB1 activation, its possible role in regulating
AMPK in the hypothalamus is discussed below.
Downstream Targets of AMPK
A full discussion of downstream targets for AMPK
are beyond the scope of this article, and readers are
referred to other reviews (23–25, 53); we focus here
mainly on some recent findings. In general, AMPK
promotes catabolic pathways that generate ATP,
while switching off ATP-consuming processes not
essential for short-term cell survival. With respect
to catabolism, AMPK acutely activates glucose and
fatty acid uptake, glycolysis, and fatty acid oxida-
tion. In the longer term, it enhances ATP genera-
tion by promoting mitochondrial biogenesis (7,
84), as well as promoting the specialized form of
autophagy called mitophagy (18), by which dys-
functional mitochondria are engulfed in autopha-
gosomes and transported to lysosomes where they
are broken down to recycle their components. Re-
cycling of bulk cytosol and organelles by au-
tophagy is a general response to starvation, which
is also activated by the AMPK ortholog in yeast
(70). In mammalian cells, an initial trigger for au-
tophagy appears to be the phosphorylation by
AMPK of the kinase ULK1 (18, 40), which then
phosphorylates and activates VPS34, a class III
phosphatidylinositol (PI) kinase that generates PI3-
phosphate (PI3P) (60). This recruits proteins con-
taining PI3P-binding domains to the membrane
that then mediate subsequent membrane traffick-
ing events. VPS34 occurs in several distinct multi-
protein complexes; interestingly, AMPK appears to
activate those complexes involved in autophagy by
phosphorylating beclin-1, while inhibiting those
involved in other membrane trafficking events by
phosphorylating VPS34 itself; this switch depends
on the presence of a third component, Atg14L, in
the former complex (39). Thus AMPK may divert
membrane traffic (an energy-requiring process)
toward the autophagy pathway and away from
other membrane trafficking events that may not be
essential in cells experiencing energy stress.
AMPK also switches off almost all biosynthetic
pathways, including synthesis of fatty acids, ste-
rols, triglycerides, phospholipids, glycogen, ribo-
somal RNA, and proteins. These pathways are
often downregulated via multiple mechanisms, in-
volving both phosphorylation of key enzymes in
the pathway and longer-term effects on gene ex-
pression. In the case of protein synthesis, the ma-
jor action of AMPK is to inhibit the mechanistic
target-of-rapamycin complex-1 (mTORC1), a cen-
tral signaling node that integrates signals arising
from growth factors, nutrient availability, and en-
ergy status, and promotes cell growth when cir-
cumstances are appropriate. mTORC1 promotes
cell growth by phosphorylating ribosomal protein
S6 kinase-1 (S6K1), by stimulating translation of
proteins critical for growth (such as ribosomal pro-
teins) and transcription of ribosomal RNA, and by
phosphorylating eIF4E binding protein-1 (4E-BP1),
relieving its inhibitory effects on translational ini-
tiation (83). Inhibition of mTORC1 by AMPK oc-
curs via dual pathways (FIGURE 3). First, AMPK
phosphorylates TSC2 (37), enhancing the Rheb-
GTPase activator function of the TSC1-TSC2 com-
plex and thus converting the G protein Rheb, an
upstream activator of mTORC1, to its inactive
GDP-bound form. Second, AMPK phosphorylates
Raptor, a subunit of the mTORC1 complex (22). A
similar dual approach is used by the insulin-
signaling pathway to activate mTORC1 and thus
oppose the effects of AMPK (FIGURE 3). The in-
sulin-activated kinase Akt phosphorylates TSC2 at
distinct sites, inhibiting its Rheb-GAP function (36,
47, 59), while also phosphorylating PRAS40, reliev-
ing its inhibitory effect on the mTORC1 complex
(62). Thus AMPK and Akt exert reciprocal control of
mTORC1. Also shown in FIGURE 3 is the inhibitory
effect of Akt on AMPK itself, discussed in the pre-
vious section.
Recently, O’Malley’s group reported that steroid
receptor co-activator-2 (SRC-2) was phosphory-
lated by AMPK and provided evidence that this
promoted transcription of mRNA encoding the bile
salt export pump, BSEP, in hepatocytes (13). Since
transport of bile salts from the liver to the gut is
required for efficient adsorption of lipids in food,
this represents an interesting mechanism by which
AMPK would enhance energy intake into the body.
Regulation of AMPK by Hormones
Given that it evolved in simple single-celled eu-
karyotes, the original primary function of AMPK ap-
pears to have been to regulate energy homeostasis
at a cell-autonomous level. However, during the
evolution of multicellular eukaryotes, hormones
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involved in regulating whole-body energy balance
have also developed the ability to regulate AMPK.
This final section of the review will focus on the
effects of these hormones, whose effects are sum-
marized in Table 1.
Ghrelin
The acylated peptide ghrelin is released from the
gut during fasting or starvation and is carried to the
hypothalamus, where it acts as a “hunger signal” to
increase appetite. Ghrelin activates AMPK in the
hypothalamus (2), and there is evidence that this is
required for ghrelin to increase food intake (3, 42).
Ghrelin receptors co-localize in the arcuate
nucleus of the hypothalamus with NPY/AgRP neu-
rons that express neuropeptide Y and agouti-re-
lated protein (72), which are required for ghrelin to
promote feeding (44). However, recent studies sug-
gest that ghrelin may act not on the NPY/AgRP
neurons themselves but on presynaptic neurons
immediately upstream (FIGURE 4). The activity of
these presynaptic neurons was assessed indirectly
in brain slices by measuring the frequency of min-
iature excitatory postsynaptic currents in the NPY/
AgRP neurons (81). Pharmacological analysis of
these currents suggested that ghrelin activates the
G-protein-coupled receptor GHSR1, triggering
production of IP3 and consequent release of intra-
cellular Ca2 in the presynaptic neuron. The re-
leased Ca2 then triggers phosphorylation of
AMPK via CaMKK (FIGURE 4). Although the mo-
lecular details beyond that point become less cer-
tain, AMPK is proposed to activate ryanodine
receptors (RyR) that also trigger Ca2 release, set-
ting up a positive feedback loop (AMPK ¡ RyR ¡
Ca2 ¡ CaMKK ¡ AMPK) that allows continued
Ca2-dependent release of the neurotransmitter
glutamate onto the NPY/AgRP neurons (and hence
feeding, via release of -MSH onto second-order
neurons), even after ghrelin release has stopped
(81). This model chimes with normal human be-
havior, since most people continue eating a meal
even after the initial hunger pangs have subsided;
cessation of feeding instead appears to require the
action of a distinct “satiety signal,” with leptin
and/or insulin being the prime candidates.
Consistent with this model, increases in food
intake induced by administration of ghrelin were
absent in mice with a whole-body knockout of
CaMKK, and the CaMKK inhibitor STO-609 also
reduced food intake in wild-type but not CaMKK
knockout mice (1). However, it should be noted
that several other mechanisms linking the hypo-
thalamic ghrelin receptor to AMPK activation
and feeding have been proposed (3, 17, 42, 69).
Leptin and Insulin
The polypeptide leptin is released from adipocytes
and can be regarded as a “satiety” signal, indicat-
ing that adipose tissue triglyceride stores are
replete (19), whereas insulin is released from pan-
creatic -cells in response to hyperglycemia. Lep-
tin causes a rapid but transient activation of
AMPK-2 complexes and hence fatty acid oxida-
tion in skeletal muscle, thus increasing energy ex-
penditure (50). Somewhat paradoxically, it has the
opposite effect in the arcuate nucleus and other
regions of the hypothalamus, where it has been
reported to inhibit AMPK-2 (49). Although leptin
is known to bind to Ob-Rb receptors in the hypo-
thalamus, there have been various proposals to
explain its inhibitory effects on AMPK. Based on
experiments in the brain slice preparation
described in the previous section, leptin was pro-
posed to trigger release of an opioid (possibly
-endorphin) from the POMC neurons, which then
FIGURE 3. Regulation of mTORC1 by the insulin/Akt and AMPK signaling
pathways
The insulin receptor activates phosphoinositide 3-kinase (PI3K), causing production of
phosphatidylinositol 3,4,5-trisphosphate (PIP3), the second messenger that switches on
the protein kinase Akt. Akt then has at least three effects: 1) it phosphorylates AMPK,
antagonizing its activation by LKB1; 2) it phosphorylates TSC2 at sites that oppose its
function as a Rheb-GAP, thus activating mTORC1; 3) it phosphorylates PRAS40, reliev-
ing its inhibitory effects on mTORC1. mTORC1 (a complex containing mTOR, Raptor,
and other components) then phosphorylates S6K1 and 4E-BP1, promoting cell growth
by enhancing translation of specific mRNAs, as well as rRNA synthesis. By contrast,
AMPK, which is activated by energy stress or by hormones that increase cytosolic Ca2
such as ghrelin, has two effects: 1) it phosphorylates TSC2 at distinct sites, enhancing
its Rheb-GAP activity; 2) it phosphorylates Raptor. These effects act to inhibit
mTORC1, protein synthesis, and cell growth.
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acts via -opioid receptors to inhibit AMPK in the
presynaptic neurons upstream of the NPY/AgRP
neurons. By interrupting the positive feedback loop
that had been set up by ghrelin, leptin would termi-
nate stimulation of the NPY/AgRP neurons and thus
feeding (81). If this model is correct, the critical pool
of AMPK is in presynaptic neurons (whose exact
identity remains uncertain) rather than in the POMC
or the NPY/AgRP neurons themselves. This would
explain why knocking out AMPK in either of the latter
neuronal types failed to abolish the anorexigenic ef-
fects of leptin (14).
Another proposal came from findings that intra-
cerebroventricular injection of leptin led not only
to decreased AMPK-2 activity in the hypothala-
mus but also to increased Ser491 phosphorylation
on AMPK-2. Leptin was also found to activate the
PI3-kinase-Akt-mTORC1-S6K1 pathway in the hy-
pothalamus, and S6K1 phosphorylated Ser491 on
AMPK-2 in cell-free assays (15). It was proposed
that Ser491 phosphorylation might inhibit Thr172
phosphorylation and consequent activation of
AMPK-2 by upstream kinases. Indeed, experi-
ments involving hypothalamic expression of S491A
mutants supported the idea that phosphorylation
of this site might be involved in the anorexigenic
effects of leptin (15). Since it has been reported
that -opioid receptors can also activate the PI3-
kinase-Akt-mTORC1-S6K1 pathway (57), this
model could be combined with the one described
in the previous paragraph. An attractive feature of
this combined model (FIGURE 4) is that insulin,
which is released after a carbohydrate meal and
has anorexigenic effects like leptin, also activates
the PI3-kinase-Akt-mTORC1-S6K1 pathway and
could therefore work via a common mechanism.
Indeed, recent studies with GTI-7 cells, a cell line
derived from mouse hypothalamus, showed that
leptin and insulin both activated S6K1 (71), al-
though in these cells ghrelin had only modest ef-
fects on AMPK and did not block the effects of
leptin or insulin on S6K1 phosphorylation (63).
Although quite compelling, the model shown in
FIGURE 4 is almost certainly over-simplified and is
unlikely to be correct in every detail. One caveat is
that it has not yet been shown that phosphoryla-
tion of Ser491 inhibits the phosphorylation of
Thr172, as does phosphorylation of Ser485 on 1
(33). It is also not yet clear whether phosphoryla-
tion of Ser485 or Ser491 inhibits Thr172 phosphor-
ylation by CaMKK.
We can thus envisage two physiological scenarios
in which leptin, insulin, and ghrelin co-regulate food
intake and energy expenditure via the neuronal
Table 1. Summary of hormones affects whole-body energy balance and their effects on AMPK
Hormone Target Cell Effect on AMPK and Mechanism Overall Effect
Ghrelin Neurons in arcuate nucleus Activation by CaMKK Increased appetite/food intake
Leptin Neurons in arcuate nucleus Inhibition (S487/S491 phosphorylation?) Decreased appetite/food intake
Insulin Neurons in arcuate nucleus Inhibition (S487/S491 phosphorylation?) Decreased appetite/food intake
Insulin Other tissues Inhibition (S487/S491 phosphorylation?) Enhanced biosynthesis, energy storage
Adiponectin Neurons in arcuate nucleus Activation via AdipoRI Increased appetite/food intake
Adiponectin Skeletal muscle, other tissues Activation via AdipoRI Increased fat oxidation/energy
expenditure
T3 Neurons in ventromedial
hypothalamus
Inhibition by unknown mechanism Activation of sympathetic nervous
system
FIGURE 4. Model for role of AMPK in controlling feeding behavior in
mammals, based on Sternson (81) and Kahn (15)
According to this combined model, the key role of AMPK is in presynaptic neurons
immediately upstream of NPY/AgRP neurons in the hypothalamus. Ghrelin causes
release of inositol 3,4,5-triphosphate (IP3) in these cells via the G-protein-coupled
receptor GHSR1, leading to release of Ca2 via IP3, thus activating CaMKK and
hence AMPK (one effect of which is to inhibit mTORC1 via the mechanisms shown in
FIGURE 3). The released Ca2 also triggers release of glutamate that activates the
downstream NPY/AgRP neurons, initiating feeding via release of AgRP onto second-
order neurons. AMPK is also proposed to activate ryanodine receptors (RyR) that
release Ca2, setting up a positive feedback loop (PFL) that allows continuous stimu-
lation of the NPY/AgRP neuron even if stimulation by ghrelin ceases. This loop is
interrupted and feeding stops when POMC neurons release an opioid onto the pre-
synaptic neuron, inhibiting AMPK via the PI3K-Akt-mTORC1-S6K1 pathway. Insulin
also depresses feeding by activating the same pathway in the presynaptic neuron.
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circuits discussed above. During negative energy
balance (fasting or starvation), ghrelin increases
and leptin and insulin decrease. This will increase
AMPK activity in the presynaptic neurons, causing
increased activity of NPY/AgRP neurons and de-
creased activity of POMC neurons, driving a pow-
erful orexigenic output (FIGURE 4). The converse
situation, following attainment of a positive energy
balance, is associated with rising leptin and insulin
and decreasing ghrelin, reducing AMPK activity
and increasing anorexigenic outputs. This circuit
appears to be dysfunctional in obese individuals
who seem to become both leptin- and insulin-
resistant in the hypothalamus, allowing ghrelin
(even at reduced levels) to escape the restraining
influences of those hormones. This would chroni-
cally elevate AMPK activity in the hypothalamus,
resulting in inappropriately activated NPY/AgRP
neurons and maintaining a prolonged hunger sig-
nal despite a positive energy balance.
As well as repressing appetite in leptin-sensitive
individuals, inhibition of AMPK by leptin in the
hypothalamus also causes activation of sympa-
thetic nerves leading to the periphery. One effect of
this is to activate AMPK-2 and stimulate fatty acid
oxidation in skeletal muscle, thus increasing whole
body energy expenditure, prolonging the more
transient direct effects of leptin on muscle (50).
These findings suggest that leptin regulates energy
balance not only by inhibiting energy intake, but
also by enhancing energy expenditure.
Adiponectin
Although secreted by adipocytes, adiponectin par-
adoxically displays high plasma levels in lean indi-
viduals and low levels in obese individuals,
suggesting that it is released when fat stores are
low. Adiponectin binds to two related receptors,
AdipoRI and AdipoRII (38), and binding to AdipoRI
activates AMPK, thus promoting fat oxidation in
liver and muscle, and inhibiting glucose produc-
tion in the liver (80). Adiponectin also increases
appetite by activating AMPK in the hypothalamus,
mimicking the effect of ghrelin but opposing the
effects of leptin (41). However, the molecular
mechanisms by which adiponectin activates AMPK
via AdipoRI remain unclear.
Thyroid Hormones
The thyroid hormone tri-iodothyronine (T3) binds to
nuclear receptors that regulate transcription and has
effects on almost all cells. However, a major effect of
T3 on whole-body energy balance appears to involve
inhibition of AMPK in neurons of the ventromedial
hypothalamus (43). Like the inhibitory effect of lep-
tin, this promotes firing of sympathetic nerves that
trigger release of norepinephrine and/or epinephrine
in the periphery. This increases energy expenditure
by stimulating release from white adipose tissue of
fatty acids, which are oxidized in other tissues, and
by promoting fat oxidation and heat production in
brown adipose tissue (43).
Conclusions and Perspectives
It is seems likely that the appearance of the AMPK
system was a very early event in evolution of eu-
karyotes, providing a mechanism for the host cell
to interact with and cooperate with its new intra-
cellular partner, the mitochondrion. As more com-
plex multicellular eukaryotes developed, this
ancestral role as a cell-autonomous energy sensor
was retained and even appears to have become
more sensitive. Thus the mammalian system is
regulated by AMPK by a very sensitive tripartite
mechanism, whereas its budding yeast ortholog
lacks at least one of these mechanisms (allosteric
activation) and also appears to be regulated by
ADP rather than AMP. In addition, new systems of
regulation have been added on top of these ances-
tral mechanisms, which allowed AMPK to play new
roles in regulating energy balance at the whole
body level. Although these additional mechanisms
are still being elucidated, they include the ability of
the starvation hormone ghrelin to activate AMPK
by the Ca2-CaMKK pathway and the ability of
insulin, and perhaps leptin, to inhibit AMPK acti-
vation by promoting phosphorylation of the ST
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